PDCD1 and neoplasm: A preclinical study reported that the simultaneous blockade of colony-stimulating factor 1 receptor (CSF1R) and anti-PD-1 antibodies resulted in reprogramming M2 TAMs into M1 and promoting tumor regression [273].